Although multiple myeloma (MM) is largely incurable, the introduction of novel frontline regimens has significantly improved survival in recent years. Following successful application in other hematologic malignancies, chimeric antigen receptor (CAR) T-cell therapies are now demonstrating impressive results in triple class-exposed MM, along with unique immune-related toxicities that must be recognized early and promptly managed. With the approval of one B-cell maturation antigen (BCMA)-directed CAR T-cell therapy and more anticipated shortly, this program will seek to educate clinicians on differences in product composition and toxicity burden, the latest available efficacy and safety data from clinical trials, strategies for selection, sequencing, and toxicity management, and effective strategies for shared decision making and patient communication specific to the CAR T-cell approach. By participating in this education, clinicians will have the improved knowledge and competence they need to leverage anti-BCMA approaches to optimize the care of patients with MM that they encounter in clinical practice today and in the near future.